Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Eton Pharmaceuticals's Enterprise Value is $1,702.0 Mil.
Eton Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $15.1 Mil. Therefore, Eton Pharmaceuticals's EV-to-OCF for today is 112.45.
The historical rank and industry rank for Eton Pharmaceuticals's EV-to-OCF or its related term are showing as below:
ETON'
s EV-to-OCF Range Over the Past 10 Years
Min: -24.06 Med: -3.02 Max: 3252.89
Current: 112.45
During the past 9 years, the highest EV-to-OCF of Eton Pharmaceuticals was 3252.89. The lowest was -24.06. And the median was -3.02.
ETON's EV-to-OCF is ranked worse than 95.03% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 10.38
vs ETON: 112.45
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eton Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Eton Pharmaceuticals's share price for today is $59.47.
Eton Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.380.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Eton Pharmaceuticals EV-to-OCF Related Terms
Eton Pharmaceuticals EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Eton Pharmaceuticals's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eton Pharmaceuticals EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Eton Pharmaceuticals's EV-to-OCF falls into.
Eton Pharmaceuticals's current Enterprise Value is $1,702.0 Mil.
Eton Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eton Pharmaceuticals (ETON) has a EV-to-OCF of 112.45 as of Sep. 09, 2026. According to the industry distribution chart, Eton Pharmaceuticals ranks #956 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 95%.
Is Eton Pharmaceuticals' EV-to-OCF too high?
Eton Pharmaceuticals' current EV-to-OCF is 112.45. The Drug Manufacturers industry median EV-to-OCF is 10.38. Eton Pharmaceuticals' value of 112.45 is 983.3% above this industry median. Based on the distribution chart, Eton Pharmaceuticals ranks #956 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eton Pharmaceuticals has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eton Pharmaceuticals' EV-to-OCF compare to ANIP and ALVO?
According to the Drug Manufacturers industry distribution chart, Eton Pharmaceuticals ranks #956 out of 1006 companies for EV-to-OCF. This places Eton Pharmaceuticals in the lower half of its industry. The industry median EV-to-OCF is 10.38. Eton Pharmaceuticals' value of 112.45 is 983.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.38, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eton Pharmaceuticals's current EV-to-OCF of 112.45 is 983.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eton Pharmaceuticals's current EV-to-OCF is 112.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eton Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Eton Pharmaceuticals (ETON) is currently considered Significantly Overvalued. The stock's GF Value™ is $25.32, compared to a current price of $59.47 — trading 134.9% above its estimated fair value. The current EV-to-OCF is 112.45 and 983.3% above the Drug Manufacturers industry median of 10.38. Eton Pharmaceuticals' overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Eton Pharmaceuticals (ETON), the current EV-to-OCF is 112.45 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eton Pharmaceuticals (ETON) Overvalued in 2026?
Based on GuruFocus' analysis, Eton Pharmaceuticals stock appears to be overvalued.
The current stock price of $59.47 is trading 134.9% above its estimated GF Value™ of $25.32.
GuruFocus considers Eton Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ETON:
EV-to-OCF: 112.45
GF Value™: $25.32 vs. price of $59.47 (134.9% above fair value)
Industry Position: 983.3% above the Drug Manufacturers median (#956 of 1006)
No single metric tells the full story. See the ETON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
64GF Score
Get the complete analysis for ETON
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ETON has been successfully added to your 
